The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to offer a greater substantial decrease in body weight and benefit metabolic functio